European Medicines Agency sees strong level of applications in 2007

European Medicines AgencyThe number of applications for marketing authorisations submitted to the European Medicines Agency (EMEA) remains strong according to the half-year report presented to the Agency's Management Board by Thomas Lönngren, EMEA Executive Director, at its 4 October 2007 meeting.

The Agency has received a total of 42 applications by mid-2007, with a further 52 forecast by the end of the year. This follows the record number of applications made to the Agency in 2006. One area of growth is applications for biosimilar medicines, with 8 applications made in the first half of 2007 and a further 8 expected by the end of the year.

Reviewing the Agency's implementation of the 2007 work programme, the Board highlighted two major achievements from the first half year. One is the Agency’s progress on implementing the new Paediatric Regulation, including the successful establishment of the Paediatric Committee (PDCO). The other is the roll-out of a new data analysis system for EudraVigilance, the European pharmacovigilance data-processing network management system, to all competent authorities in the EU Member States, which has significantly improved the systems capabilities to monitor the safety of medicines.

The Management Board also adopted the EU telematics master plan that aims to provide a coherent development strategy for 2007-2013 for EU telematics – the set of pan-European IT systems and databases used for the collection and dissemination of information on medicines in the European Union.

The second status report on the implementation of the EMEA road map to 2010 was presented to the Management Board and will be published on the EMEA website. The report highlights progress made in 2006 and the first half of 2007 in areas that include improving safety of medicines; stimulating research and innovation in partnership with European institutions; improving availability to medicines; strengthening the provision of information and interaction with Agency stakeholders; reinforcing international collaboration; and strengthening the European Union regulatory system for medicines. Stepping up the implementation, a new action plan is currently under preparation, which will set out the initiatives to be undertaken in 2008 and 2009.

For further information, please visit:
www.emea.europa.eu

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...